** Eli Lilly LLY.N shares dip 1.4% premarket to $872.32 after HSBC double downgrades rating to "reduce" from "buy"
** Brokerage also cuts TP to $700 from $1150, saying there is "too much optimism in the price"
** HSBC says obesity drug sector is sensitive to macro environment and sector's growth risk due to higher unemployment numbers is unknown
** "We prefer Novo (Nordisk) over Lilly at the current share price", HSBC adds
** Brokerage also downgrades Roche ROG.S, Biogen BIIB.O to "hold" from "buy," citing forex and China diagnostics risks for Roche and slow Alzheimer's adoption for Biogen
** 23 out of 29 analysts rate stock "buy" or higher, 5 "hold" and 1 "sell", median PT is $1000, as per LSEG data
** YTD, Of last close, LLY up 14.6%, ROG up 3.6% and BIO down 22.3%
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。